ARTICLE | Emerging Company Profile
Nvelop: Delivering gene editors to specific cells via virus-like particles
Propelled by $100M in seed funding, Cambridge, Mass.-based biotech is developing dual virus-like particle platforms from two gene editing pioneers
August 30, 2024 1:08 AM UTC
With a focus on in vivo gene editing and $100 million in seed funding, Nvelop is combining two labs’ technologies to engineer virus-like particles with cell-specific tropism, which it believes will be safer and more versatile than other delivery platforms.
Nvelop Therapeutics Inc. is one of dozens of companies venturing beyond adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs) — the two dominant oligonucleotide delivery vehicles in industry pipelines — to deliver therapeutic cargo to specific cells and tissues...